NCT04313075

A Compassionate Use Study of Leronlimab in Breast Cancer

A Compassionate Use Study of Leronlimab (PRO 140) Plus Treatment of Physician's Choice in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: CytoDyn, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: —

Summary

This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.

Detailed description

This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with chemokine receptor 5 (CCR5+) mTNBC. Leronlimab (PRO 140) will be administered subcutaneously as a weekly dose of 350 or 525 mg until disease progression or intolerable toxicity. Treatment of Physician's Choice (TPC) is defined as one of the following single-agent chemotherapy drugs administrated according to local practice: eribulin, gemcitabine, capecitabine, paclitaxel, nab-paclitaxel, vinorelbine, ixabepilone, or carboplatin. The selected treatment should be administered as per the dosing schedule included on the package insert. In this study, patients will be evaluated for tumor response approximately every 3 months or according to institution's standard practice by computed tomography (CT), positron emission computed tomography (PET/CT) or MRI with contrast (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be done using RECIST v1.1.

Conditions

• Metastatic Triple-Negative Breast Carcinoma

Interventions

Type	Name	Description
DRUG	Leronlimab	Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Timeline

• First posted: 2020-03-18
• Last updated: 2025-07-15